R&D 5 strategies for biopharma to optimise patient recruitment i... Patient recruitment remains a significant challenge for biopharma companies, often leading to delays and increased costs in clinical trials.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.